American Society of Hematology

ASH is committed to helping practicing hematologists provide quality care to patients, continue their professional development, and enhance their knowledge and expertise.

Guidelines and Quality Care

Resources to help practicing hematologists improve the quality
of care provided to patients

Drug Resources

Newly approved therapies and access information on hematologic drugs

Consult a Colleague

Service that provides advice on clinical questions in one to two days

Professional Development

Services to support hematologists with continuing medical education and recertification

Practice Resources

Resources to help hematologists understand federal programs, policy developments, and relevant issues affecting clinical practice

ASH Practice Update

Email newsletter highlighting the Society's latest educational offerings and developments impacting clinicians

View all Ask the Hematologist
  • FDA Approves Filgrastim-sndz as a Biosimilar to US-licensed Filgrastim (Neupogen)

    On March 6, 2015, the U. S. Food and Drug Administration approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to US-licensed Neupogen for the five indications for which US-licensed Neupogen is approved. The formulation of ZARXIO differs from that of US-licensed Neupogen in one inactive component.

  • FDA Grants Accelerated Approval to Panobinostat for Multiple Myeloma

    On February 23, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to panobinostat (FARYDAK® capsules, Novartis Pharmaceuticals) in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. As a condition of this accelerated approval, FDA requires the sponsor to conduct a trial to verify and describe the clinical benefit of panobinostat for patients with multiple myeloma.

  • FDA Approves ibrutinib to Treat Rare Form of non-Hodgkin lymphoma

    On January 29, 2015 the U.S. Food and Drug Administration approved ibrutinib (Imbruvica® Capsules, Pharmacyclics, Inc.) for the treatment of patients with Waldenstrom’s macroglobulinemia (WM).

  • FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia

    The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.

View all FDA alerts
View all policy news
back to top